Related Experiment Video

Updated: Jan 15, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

713

Risk of New-Onset Ischaemic and Haemorrhagic Stroke in Patients With Type 2 Diabetes With Chronic Kidney Disease on

Ya-Hui Lin1,2, Tsung-Kun Lin3,4, Pei-Lun Liao5

  • 1College of Nursing, Central Taiwan University of Science and Technology, Taichung, Taiwan (ROC).

Diabetes/Metabolism Research and Reviews
|January 14, 2026
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the risk of both ischaemic and haemorrhagic strokes in patients with type 2 diabetes and chronic kidney disease. This finding supports SGLT2i as a potential clinical option for stroke prevention in this high-risk population.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Type 2 diabetes and chronic kidney disease are significant risk factors for both ischaemic and haemorrhagic strokes.
  • The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in mitigating stroke risk in patients with co-existing type 2 diabetes and chronic kidney disease requires further elucidation.

Purpose of the Study:

  • To investigate the efficacy of SGLT2 inhibitors in preventing incident ischaemic and haemorrhagic strokes among patients with type 2 diabetes and chronic kidney disease.

Main Methods:

  • A retrospective cohort study utilizing propensity score matching (1:1) and Cox regression analysis to compare stroke incidence between SGLT2i users and non-users.
  • Kaplan-Meier analysis assessed long-term stroke risk.
  • Sensitivity analysis with 1:2 sex and age matching further validated the findings.

Main Results:

  • Analysis included 107,819 SGLT2i users and 107,819 non-users after propensity score matching.
  • SGLT2i therapy demonstrated a significant reduction in the incidence of ischaemic strokes (HR 0.86, 95% CI 0.81-0.90) and haemorrhagic strokes (HR 0.80, 95% CI 0.74-0.87).
  • Sensitivity analyses confirmed the significant protective effect of SGLT2i against both stroke types.

Conclusions:

  • SGLT2 inhibitors effectively reduce the risk of incident ischaemic and haemorrhagic strokes in patients concurrently diagnosed with type 2 diabetes and chronic kidney disease.
  • The demonstrated protective effects position SGLT2 inhibitors as a viable clinical strategy for stroke prevention in this vulnerable patient group.
Abstract

Keywords:
SGLT2 inhibitorshaemorrhagic strokeischaemic stroketype 2 diabetes

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.6K
Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
547
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
257
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
557
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K